Aggressive fibromatosis Desmoid tumors
Conditions
Interventions
watchful waiting policy
Sponsors
Erasmus MC Cancer Institute
Eligibility
Inclusion criteria
Inclusion criteria: - Histological evidence of aggressive fibromatosis. - Capable of undergoing MRI-scans and ultrasound. - Nu functional impairment due to the tumor. - Capable of understanding and signing informed consent.
Exclusion criteria
Exclusion criteria: - Patients under 18 years of age. - Personal of family history of FAP. - Intra-abdominal tumor localization. - Potential life treat or imminent functional impairment in case of tumor progression. - Unavoidable mutilation in case of tumor progression. - Severe pain associated with the tumor. - Patients who have undergoing local or systemic treatment for the present manifestation of aggressive fibromatosis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess tumor progression in terms of objectifying and monitoring growth during watchful waiting policy as an initial treatment for extra-abdominal and abdominal wall aggressive fibromatosis. | — |
Secondary
| Measure | Time frame |
|---|---|
| To investigate quality of life during a watchful waiting approach. To analyze the willingness of patients to adhere to a watchful waiting policy. To analyze the value of clinicopathological factors, including CTNNB1-gene mutation, in predicting progression. In case of objectified progression: to analyze considerations for administered treatment. | — |
Contacts
Public ContactD. Broekhoven, van
Erasmus MC Cancer Institute
Outcome results
None listed